B/F/TAF Placebo

DRUG5 trials

Conditions

HIV-1 InfectionHIV-1-infection

Phase 3

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

CompletedNCT02603120

Gilead SciencesHIV-1 Infection

Start: 2015-11-11End: 2019-10-23Updated: 2020-11-12

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02607956

Gilead SciencesHIV-1 Infection

Start: 2015-11-11End: 2021-07-05Updated: 2022-03-07

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

CompletedNCT02607930

Gilead SciencesHIV-1 Infection

Start: 2015-11-13End: 2021-07-02Updated: 2022-03-02

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

CompletedNCT03110380

Gilead SciencesHIV-1-infection

Start: 2017-06-12End: 2021-02-10Updated: 2022-01-11

Phase 4

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

TerminatedNCT03532425

University of AlbertaHIV-1-infection

Start: 2018-10-29End: 2020-09-03Updated: 2022-12-14

2025-04-071 citations

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with <scp>HIV</scp>‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies

HIV Medicine2025-03-21

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study

Medicine2025-02-212 citations

P-547. Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

P-550. Efficacy and Safety of B/F/TAF in Black Adults with HIV Who Are Treatment Naïve: 5-Year Follow-Up from Two Phase 3 Studies

Open Forum Infectious Diseases2025-01-29

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

UNC Libraries2024-12-04

Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy

Journal of Antimicrobial Chemotherapy2024-11-185 citations

Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary

Future Microbiology2024-09-041 citations

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS2024-02-1311 citations

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.

2023-05-1162 citations

Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials

HIV Medicine2022-08-178 citations

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants

Open Forum Infectious Diseases2021-11-01

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

UNC Libraries2020-08-187 citations

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical Infectious Diseases2020-07-10103 citations

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

2020-06-01101 citations

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

2019-05-05119 citations

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

2019-05-05103 citations

Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine.

2018-10-0148 citations

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

2018-06-18148 citations

2017-08-31276 citations

1 more papers not shown

B/F/TAF Placebo

Sponsors

Conditions

Phase 3

Phase 4

Related Papers